Citation Impact
Citing Papers
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
2013 Standout
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
2013 Standout
The human disease network
2007 Standout
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
2010 Standout
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary
2014 Standout
Cochrane Database of Systematic Reviews
2003 Standout
No health without mental health
2007 Standout
A concise history of gout and hyperuricemia and their treatment.
2006
Coronary Artery Calcium Score for Long-term Risk Classification in Individuals With Type 2 Diabetes and Metabolic Syndrome From the Multi-Ethnic Study of Atherosclerosis
2017
Thiazolidinediones
2004 Standout
Demethylation of 3-Methylthymine in DNA by Bacterial and Human DNA Dioxygenases
2004 StandoutNobel
Nonalcoholic Fatty Liver Disease: From Steatosis to Cirrhosis
2006 Standout
Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis
2010
Steroid reversibility test followed by inhaled budesonide or placebo in outpatients with stable chronic obstructive pulmonary disease
1999
The impact of atherosclerotic renovascular disease on diabetic renal failure
2002
Meta-Analysis of the Relationship Between Non–High-Density Lipoprotein Cholesterol Reduction and Coronary Heart Disease Risk
2009
Bezafibrate for the Secondary Prevention of Myocardial Infarction in Patients With Metabolic Syndrome
2005
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
2011 Standout
Reliability and validity of blood pressure measurement in the Secondary Prevention of Small Subcortical Strokes study
2007
Levels of the adipocyte-derived plasma protein, adiponectin, have a close relationship with atheroma
2005
Structure of Human Phytanoyl-CoA 2-Hydroxylase Identifies Molecular Mechanisms of Refsum Disease*
2005
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
2005 Standout
Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes
2002
Exercise Standards for Testing and Training
2013 Standout
The Human Intestinal Microbiome in Health and Disease
2016 Standout
Steatohepatitis in children
2002
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
2015 Standout
Aspirin plus Clopidogrel as Secondary Prevention after Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis
2014 Standout
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
2004 Standout
Gout
2009 Standout
The mercury sphygmomanometer should be abandoned before it is proscribed
2000
GRADE guidelines: 8. Rating the quality of evidence—indirectness
2011
EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT)
2006 Standout
Major Lipids, Apolipoproteins, and Risk of Vascular Disease
2009 Standout
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer
2013 StandoutNobel
Obesity
2005 Standout
Drug Treatment of Lipid Disorders
1999
Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM
1995
Micronised Fenofibrate
2002
Platelet Activation and Atherothrombosis
2007 Standout
Type 2 diabetes
2017 Standout
Diabetes and Atherosclerosis
2002 Standout
Gout
2016 Standout
HIV-induced alteration in gut microbiota
2014
Prevalence of anxiety in adults with diabetes
2002
Gout in Solid Organ Transplantation
2005
Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
2012
Selective recording in blood pressure readings may increase subsequent mortality
2002
2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults
2010
Mycobacterium tuberculosis Rv3406 Is a Type II Alkyl Sulfatase Capable of Sulfate Scavenging
2013 StandoutNobel
Crystal Structure of the Non-heme Iron Dioxygenase PtlH in Pentalenolactone Biosynthesis
2007 StandoutNobel
British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Gout
2007
Diabetes, Plasma Insulin, and Cardiovascular Disease
2002
Progress and challenges in translating the biology of atherosclerosis
2011 StandoutNature
Phosphatase and tensin homolog (PTEN) regulates hepatic lipogenesis, microsomal triglyceride transfer protein, and the secretion of apolipoprotein B–containing lipoproteins
2008 StandoutNobel
Lipid signalling couples translational surveillance to systemic detoxification in Caenorhabditis elegans
2015 StandoutNobel
Can change in high-density lipoprotein cholesterol levels reduce cardiovascular risk?
2004
Current management of gout in patients unresponsive or allergic to allopurinol
2004
Fe(II)/α-Ketoglutarate-Dependent Hydroxylases and Related Enzymes
2004
Peroxisome biogenesis disorders
2006
High‐molecular intestinal alkaline phosphatase in chronic liver diseases
2007
Uric acid nephrolithiasis
2007
Mutations in the Gene Encoding Peroxisomal Sterol Carrier Protein X (SCPx) Cause Leukencephalopathy with Dystonia and Motor Neuropathy
2006
Clinical Practice Guidelines and Quality of Care for Older Patients With Multiple Comorbid Diseases
2005 Standout
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease
2012 Standout
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial
2005 Standout
Diagnosis and Management of the Metabolic Syndrome
2005 Standout
Diabetes Enhances Vulnerability to Particulate Air Pollution–Associated Impairment in Vascular Reactivity and Endothelial Function
2005
Diabetic Nephropathy: Diagnosis, Prevention, and Treatment
2005 Standout
Platelet Degranulation Is Associated With Progression of Intima-Media Thickness of the Common Carotid Artery in Patients With Diabetes Mellitus Type 2
2005
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
Target intervention against multiple‐risk markers to reduce cardiovascular disease in patients with type 2 diabetes
2004
Hypertriglyceridemic HyperapoB: The Unappreciated Atherogenic Dyslipoproteinemia in Type 2 Diabetes Mellitus
2001
Evidence-Based Nutrition Principles and Recommendations for the Treatment and Prevention of Diabetes and Related Complications
2002
A vesicle carrier that mediates peroxisome protein traffic from the endoplasmic reticulum
2010 StandoutNobel
Aggregation-Induced Emission: Together We Shine, United We Soar!
2015 Standout
Type 2-diabetes og det metaboliske syndrom - diagnostik og behandling
2000
Exercise Training for Type 2 Diabetes Mellitus
2009
Pleiotropic Actions of Peroxisome Proliferator–Activated Receptors in Lipid Metabolism and Atherosclerosis
2002
Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence: A Scientific Statement From the American Heart Association and the American Diabetes Association
2015
Anxiety and Poor Glycemic Control: A Meta-Analytic Review of the Literature
2002
Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes
2008 Standout
Peroxisome Biogenesis Disorders
2003
Diabetes Mellitus
2000
Update on Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes Mellitus in Light of Recent Evidence
2015
Comparison of Coronary Artery Calcium Scores Between Patients With Psoriasis and Type 2 Diabetes
2016
Gout
2021 Standout
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481]
2004
2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults
2010
Particulate Matter Air Pollution and Cardiovascular Disease
2010 Standout
Lipids and Lipoproteins in Patients With Type 2 Diabetes
2004
Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
2004 Standout
Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity
2017 StandoutNobel
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis
2020 Standout
Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin
2002 Standout
Recommendations for Blood Pressure Measurement in Humans and Experimental Animals
2005 Standout
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
Works of Michael Feher being referenced
Metabolic-Inflammatory Changes, and Accelerated Atherosclerosis in HIV Patients: Rationale for Preventative Measures
2008
Injection related anxiety in insulin-treated diabetes
1999
The association of coronary calcium score and conventional cardiovascular risk factors in Type 2 diabetic subjects asymptomatic for coronary heart disease (The PREDICT Study)
2004
Statin Therapy-Evidence Beyond Lipid Lowering Contributing to Plaque Stability
2006
Diabetes: preventing coronary heart disease in a high risk group
2004
Atherogenic lipoprotein phenotype in Type 2 diabetes: reversal with micronised fenofibrate
1999
Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout
2003
Coronary calcium measurement improves prediction of cardiovascular events in asymptomatic patients with type 2 diabetes: the PREDICT study
2008
Lipid lowering to delay the progression of coronary artery disease
2003
Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study
2018
Long-term remission from gout associated with fenofibrate therapy
2003
Steroid trials in the assessment of reversibility of air flow limitation: a survey of current clinical practice of chest physicians
1991
Refsum's disease: a peroxisomal disorder affecting phytanic acid α‐oxidation
2002
Diabetic Macrovascular Disease and Serum Lipids: Is There a Connection?
1992
Triglyceride Fatty Acid Chain Length Influences the Post Prandial Rise in Serum Intestinal Alkaline Phosphatase Activity
1992
Metformin therapy for diabetes in Prader-Willi syndrome
1998
Blood pressure measurement in the community: do guidelines help?
1996
Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease.
1995
Cardiovascular Outcomes in Type 2 Diabetes: A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study
1998
Prevalence of renal artery stenosis in subjects with type 2 diabetes and coexistent hypertension.
2000